Histopathology of endometrial hyperplasia and endometrial carcinoma: an update
- PMID: 17630117
- DOI: 10.1016/j.anndiagpath.2007.05.002
Histopathology of endometrial hyperplasia and endometrial carcinoma: an update
Abstract
Endometrial cancer (EC) is the most common malignancy of the female genital tract in the western world. Conceptually, a dualistic model of endometrial carcinogenesis exists for sporadic EC, based on molecular findings with a good correlation to the morphologic phenotype and clinical behavior. Type 1 endometrial carcinoma represents an estrogen-related tumor, which usually arises in the setting of endometrial hyperplasia, has endometrioid histology with low grade, and tends to be biologically indolent. Grade 3 endometrioid cancers, which constitute a minority of EC, also behave aggressively. The type 2 cancers are not estrogen-driven and have a higher grade, various histologies, particularly serous carcinomas and clear-cell carcinomas, and a poorer prognosis. The diagnostic criteria of endometrial hyperplasia, endometrial in situ carcinoma, and of the different histologic types of EC, according to the most recent World Health Organization classification, are given in detail. In addition, the risk of progression of endometrial hyperplasia into endometrioid type EC and their treatment modalities are discussed. Endometrial pathologies in patients with breast cancer, receiving tamoxifen, and women affected by hereditary nonpolyposis colorectal cancer syndrome are described, including their pathogenetic aspects. Finally, a short practical description for the handling of surgical specimens from fractional curetting and hysterctomies is given.
Comment in
-
Histopathology of endometrial hyperplasia and endometrial carcinoma. An update by Dr LC Horn et al in Annals of Diagnostic Pathology 2007;11:297-311.Ann Diagn Pathol. 2008 Jun;12(3):231-2; author reply 232-3. doi: 10.1016/j.anndiagpath.2008.02.004. Ann Diagn Pathol. 2008. PMID: 18486902 No abstract available.
Similar articles
-
Molecular carcinogenesis of endometrial cancer.Taiwan J Obstet Gynecol. 2007 Mar;46(1):26-32. doi: 10.1016/S1028-4559(08)60102-3. Taiwan J Obstet Gynecol. 2007. PMID: 17389185 Review.
-
Histopathology of endometrial hyperplasia and endometrial carcinoma. An update by Dr LC Horn et al in Annals of Diagnostic Pathology 2007;11:297-311.Ann Diagn Pathol. 2008 Jun;12(3):231-2; author reply 232-3. doi: 10.1016/j.anndiagpath.2008.02.004. Ann Diagn Pathol. 2008. PMID: 18486902 No abstract available.
-
[Precancerous lesion of the endometrium and endometrial morphology in patients with tamoxifen therapy].Zentralbl Gynakol. 2002 Jan;124(1):3-9. doi: 10.1055/s-2002-20315. Zentralbl Gynakol. 2002. PMID: 11873307 Review. German.
-
Theories of endometrial carcinogenesis: a multidisciplinary approach.Mod Pathol. 2000 Mar;13(3):295-308. doi: 10.1038/modpathol.3880051. Mod Pathol. 2000. PMID: 10757340 Review.
-
Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.Gynecol Oncol. 2005 Aug;98(2):274-80. doi: 10.1016/j.ygyno.2005.04.027. Gynecol Oncol. 2005. PMID: 15972232
Cited by
-
Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma.Clin Epigenetics. 2015 Mar 10;7(1):20. doi: 10.1186/s13148-015-0059-3. eCollection 2015. Clin Epigenetics. 2015. PMID: 25767621 Free PMC article.
-
Comparison of WHO and endometrial intraepithelial neoplasia classifications in predicting the presence of coexistent malignancy in endometrial hyperplasia.J Gynecol Oncol. 2010 Jun;21(2):97-101. doi: 10.3802/jgo.2010.21.2.97. Epub 2010 Jun 30. J Gynecol Oncol. 2010. PMID: 20613899 Free PMC article.
-
Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma.Aging (Albany NY). 2021 Nov 27;13(22):24686-24709. doi: 10.18632/aging.203710. Epub 2021 Nov 27. Aging (Albany NY). 2021. PMID: 34837690 Free PMC article.
-
IL-37bΔ1-45 suppresses the migration and invasion of endometrial cancer cells by targeting the Rac1/NF-κB/MMP2 signal pathway.Lab Invest. 2021 Jun;101(6):760-774. doi: 10.1038/s41374-021-00544-2. Epub 2021 Mar 22. Lab Invest. 2021. PMID: 33753880
-
The reduced PDCD5 protein is correlated with the degree of tumor differentiation in endometrioid endometrial carcinoma.Springerplus. 2016 Jul 7;5(1):988. doi: 10.1186/s40064-016-2698-z. eCollection 2016. Springerplus. 2016. PMID: 27398268 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
